Useful contact

– For recruitment and internship files: rhcom.u1149@inserm.fr

– For your orders : commandes.u1149@inserm.fr

– To request a computer intervention: info.u1149@inserm.fr

– For Health and Safety questions: hs.u1149@inserm.fr

– Website editorial committee: To propose news, events and publications to add to the website: cellcom.u1149@inserm.fr


 
Renato Monteiro

Glomerulonephritis & Immunoreceptors (GLOMI)

Team Monteiro / Flamant

Department Nephrology, Immunology and Hematology

 

Leader(s)

 

Line-up

 

Presentation

Chronic kidney diseases (CKD) are a growing health problem worldwide as they lead to renal failure with so far limited treatment options. Approximately 10% of the general population have renal insufficiency, of which 5.6% at a light or moderate stage, 3.7% at a severe stage and 0.13% at the terminal stage needing dyalisis or transplantation as replacement therapy. CKD can be caused by disorders such as glomerulonephritis (GN). Among the GN, IgA nephropathy (IgAN), Lupus nephritis (LN) and idiopathic nephrotic syndrome (INS) are major causes of end-stage renal disease worldwide. Understanding mechanisms leading to IgAN, LN or INS are crucial to design new therapeutic strategies.  Our team is one of the world leaders in IgAN field (www.iigann.com). We described that a soluble form of the CD89 (sCD89), an IgA Fc receptor, is part of nephritogenic mesangial IgA deposits and identified the Transferrin Receptor 1 (TfR1) as the IgA1 mesangial receptor in IgAN. We also showed that the TfR1 binds to IgA1 in a physiological way, promoting erythroblast proliferation. In IgAN physiopathology, TfR1 is overexpressed on mesangial cells with preferential affinity for deglycosylated IgA1 and induces proliferation of mesangial cells via the PI3K/Akt pathway, and production of inflammatory cytokines via the MAPK/Erk pathway. In other studies, we have shown that abnormalities  of  IgA1  glycosylation,  a  galactose-­‐deficient  (Gd)  IgA1,  also  arise  in  alcoholic  cirrhosis  (AC),  including mesangial IgA deposits with possible development of secondary IgAN indicating that common environmental factors (such as bacteria translocation at portal vein) may influence the IgAN development6. Moreover, we developed a new humanized  mouse  model  of  IgAN:  alpha1KI-CD89Tg  mice,  in  which  sCD89  plays  a  pivotal  role  in  IgAN  inducing  the formation of mesangial nephritogenic deposits, mesangial TfR1 and transglutaminase 2 (TG2) overexpression. Ablation of TG2 gene resulted in protection from the disease, showing for the first time that TG2 plays a crucial role in IgAN development. We have also studied the mechanisms involved in celiac disease (CD) and showed similarities with IgAN. In collaborative studies,  we  showed  an  increase  of  IgA  complexes  containing  a  gliadin peptide and apical expression of TfR1 on enterocytes in active CD patients. This overexpression could allow the retrograde transcytosis of gliadin peptide from apical to basal side of enterocytes. Moreover, we demonstrated that gluten sensitivity in mice leads to a CD phenotype, associated with overexpression of TfR1 and TG2, as well as overproduction of IgA and that it exacerbates IgAN.

Concerning our fundamental research on immunoregulation through Fc receptors (FcRs), we have shown, in a tight consortium with the team of U. Blank in the research unit, that CD89 (FcalphaRI), CD16 (FcgammaRIII) and CD32A (FcgammaRIIA), all receptors containing immunoreceptor tyrosine-based activation motifs (ITAM), are switch molecules which can induce either inhibition or cell activation, depending on their ligand configuration  (mono/divalent versus multivalent) leading to inhibition (ITAMi) or activation (ITAMa), respectively. Targeting CD89 inhibited the appearance of inflammation in lungs, joints and  kidneys. IVIg also induces  ITAMi-mediated  inhibition  through  CD16A  and  CD32A  for  IVIgG  or through CD89 for IVIgA. In another hand, we have shown that E Coli is able to directly bind to CD16 and induce an ITAMi-mediated inhibition of phagocytosis, allowing E coli to escape the immune system. Our recent studies have shown that CD89 acts an innate receptor for bacteria that protects from sepsis through ITAMa-signaling pathway.

Our studies include 5 work-packages:

WP1. Understanding physiopathology of IgAN:

  1. To determine the role of the transglutaminase 2 in IgAN and
  2. To characterize the gut-kidney axis in IgAN;

WP2. Identification of autoantibodies in idiopathic nephrotic syndrome;

WP3. Src kinases as pronostic biomarkers in autoimmune GN:

  1. To establish Fyn effectors (phosphorylated SHP-1S591 and PKC-α) as prognostic biomarkers for autoimmune GN and
  2. To identify new specific prognostic markers for GN severity.

WP4. New therapeutic approaches for GN that are currently developped by targeting immunoreceptors as new anti-inflammatory therapeutic approaches in collaboration with an spinoff Inatherys (www.inatherys.com).

WP5. Studies on hypertension and lithium induced renal toxicity.

Team strengths are :

  1. Strong interaction with Bichat and Robert Debré hospitals (Nephrology, Physiology, Immunology).
  2. Available biobanks: 5 different cohorts of patients (Nephrotest, Henoch-Schonlein purpura, INS-nephrochain, GN Bichat, and MicrobIgAN cohorts).
  3. Mouse models of renal diseases (humanized model for IgAN, transgenic, KO mice), kidney-derived primary cells (mesangial cells, podocytes…).
  4. An active partner of the INFLAMEX Labex.
 

Landmark publications

  • Publication date : 07 March 2024 More

    Identification of a Direct Role for Gut-Flora in Autoimmune Disease
    Sci Transl Med.

    Authors : Patrick J Gleeson Nicolas Benech Jonathan Chemouny Eleftheria Metallinou Laureline Berthelot Da silva Jennifer Bex-Coudrat Julie Boedec Erwan Fanny Canesi Bounaix Carine Willy Morelle Maryse Moya-Nilges John Kenny Liam O'Mahony Saveanu Loredana Bertrand Arnulf Aurélie Sannier Daugas Eric Vrtovsnik François Patricia Lepage Harry Sokol Monteiro Renato

  • Publication date : 01 October 2019 More

    Extracellular fluid volume is associated with incident end-stage kidney disease and mortality in patients with chronic kidney disease.
    Kidney Int.

    Authors : Faucon AL Flamant Martin Metzger M Boffa JJ Haymann JP Houillier P Thervet E Vrtovsnik François Stengel B Geri G Vidal-Petiot Emmanuelle NephroTest Study Group

  • Publication date : 01 July 2019 More

    Modulation of the microbiota by oral antibiotics treats immunoglobulin A nephropathy in humanized mice.
    Nephrol Dial Transplant.

    Authors : Chemouny JM Gleeson PJ Abbad L Lauriero G Boedec Erwan Le Roux K Monot C Bredel M Bex-Coudrat Julie Sannier A Daugas Eric Vrtovsnik François Gesualdo L Leclerc M Berthelot L Ben Mkaddem Sanae Lepage P Monteiro Renato

  • Publication date : 16 April 2019 More

    CD89 Is a Potent Innate Receptor for Bacteria and Mediates Host Protection from Sepsis.
    Cell Rep.

    Authors : De Tymowski Christian Heming N Correia MDT Abbad L Le Stang Marie-Bénédicte Flament Heloise Bex J Boedec Erwan Bounaix Carine Soler-Torronteras R Denamur E Galicier L Oksenhendler E Fehling HJ Pinheiro da Silva F Benhamou Marc Monteiro Renato Ben Mkaddem Sanae

  • Publication date : 01 December 2017 More

    Serum Iron Protects from Renal Postischemic Injury.
    J Am Soc Nephrol.

    Authors : Vaugier C Amano MT Chemouny JM Dussiot M Berrou C Matignon M Ben Mkaddem Sanae Wang PHM Fricot A Maciel TT Grapton D Mathieu JRR Beaumont Carole Peraldi MN Peyssonnaux C Mesnard L Daugas Eric Vrtovsnik François Monteiro Renato Hermine O Ginzburg YZ Benhamou Marc Camara NOS Flamant Martin Moura IC

  • Publication date : 15 August 2017 More

    Lyn and Fyn function as molecular switches that control antigen receptors directing homeostasis or inflammation
    Nat Comm, in press.

    Authors : Ben Mkaddem Sanae Murua Amaya Flament Heloise Titeca Dimitri Bounaix Carine Danelli Luca Launay Pierre Benhamou Marc Blank Ulrich Daugas Eric Charles Nicolas Monteiro Renato

  • Publication date : 01 September 2016 More

    IgA1 Protease Treatment Reverses Mesangial Deposits and Hematuria in a Model of IgA Nephropathy.
    J Am Soc Nephrol.

    Authors : Lechner SM Abbad L Boedec Erwan Papista C Le Stang Marie-Bénédicte Moal C Maillard J Jamin A Bex-Coudrat Julie Wang Y Li A Martini PG Monteiro Renato Berthelot L.

  • Publication date : 26 August 2016 More

    Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study
    Lancet.

    Authors : Vidal-Petiot Emmanuelle Ford I Greenlaw N Ferrari R Fox KM Tardif JC Tendera M Tavazzi L Bhatt TL Steg PG CLARIFY Investigators

  • Publication date : 01 October 2015 More

    Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes.
    Kidney Int.

    Authors : Berthelot L Robert T Vuiblet V Tabary T Braconnier A Dramé M Toupance O Rieu P Monteiro Renato Touré F

  • Publication date : 01 August 2015 More

    Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction.
    Kidney Int.

    Authors : Papista C Lechner S Le Stang Marie-Bénédicte Ben Mkaddem Sanae Bex-Coudrat Julie Pillebout Evangéline Chemouny J Jablonski M Flamant Martin Daugas Eric Vrtovsnik François Yiangou M Berthelot L Monteiro Renato

  • Publication date : 25 July 2014 More

    Shifting FcγRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis
    J Clin Invest.

    Authors : Ben Mkaddem Sanae Hayem G Jönsson F Rossato E Boedec Erwan Boussetta T El Benna Jamel Launay Pierre Goujon JM Benhamou Marc Bruhns P Monteiro Renato

  • Publication date : 26 March 2012 More

    Transglutaminase is essential for IgA nephropathy development acting through IgA receptors
    J Exp Med.

    Authors : Berthelot L Papista C Maciel TT Biarnes-Pelicot M Tissandie E Wang PH Tamouza H Jamin A Bex-Coudrat Julie Gestin A Boumediene A Arcos-Fajardo M England P Pillebout Evangéline Walker Francine Daugas Eric Vrtosvnik F Flamant Martin Benhamou Marc Cogné M Moura IC Monteiro Renato

 
 

Site de référence pour les Appels à Projets


Les dernières publications marquantes

  • Publication date : 09 April 2024 More

    Prognosis algorithms for acute decompensation of cirrhosis and ACLF
    Liver Int.

    Authors : Valainathan Shantha Qing Xie Vicente Arroyo Rautou Pierre-Emmanuel

  • Publication date : 01 March 2024 More

    Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease is associated with heterogeneous pattern of fat infiltration in skeletal muscles
    Eur Radiol.

    Authors : Maxime Nachit Dioguardi Burgio Marco Abyzov Anton Garteiser Philippe Paradis Valérie Vilgrain Valérie Isabelle Leclercq Van Beers Bernard

  • Publication date : 27 February 2024 More

    Predictive Role of Hepatic Venous Pressure Gradient in Bleeding Events Among Cirrhotic Patients Undergoing Orthotopic Liver Transplantation
    JHEP Rep.

    Authors : Mikhael Giabicani Pauline Joly Stéphanie Sigaut Clara Timsit Pauline Devauchelle Fédérica Dondero Durand François Pierre Antoine Froissant Myriam Lamamri Payancé Audrey Aymeric Restoux Olivier Roux Tristan Thibault-Sogorb Shantha Ram Valainathan Lesurtel Mickaël Rautou Pierre-Emmanuel Weiss Emmanuel